Collegium Pharmaceutical (COLL) Earnings Analysis

Collegium Pharmaceutical (COLL) next reports earnings on 2026-08-06, consensus EPS 1.68 USD. Last quarter (2026-05-07) it beat with EPS 1.76 USD vs 1.52 USD est (+15.8%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 14.65.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does COLL next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate1.68 USD
Revenue estimate0.20B

COLL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-071.76 USD1.52 USD+15.8%Beat
2026-02-262.04 USD2.14 USD-4.7%Miss
2025-11-062.25 USD1.86 USD+21%Beat
2025-05-081.49 USD1.43 USD+4.2%Beat
2025-02-271.77 USD1.54 USD+14.9%Beat
2024-11-071.61 USD1.59 USD+1.3%Beat

Beat rate: 5/6 (83%) over reported quarters with consensus data.

COLL valuation and analyst view

Trailing P/E14.65
Trailing EPS2.336 USD
Price / book3.57
Dividend yield0.00%
Market cap1.13B
Analyst consensusBuy (8 buy / 3 hold / 1 sell)
Avg price target57.4 USD

Related research pages

Frequently asked questions

When is Collegium Pharmaceutical (COLL)'s next earnings date?

Collegium Pharmaceutical is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 1.68 USD and revenue estimate of 0.20B.

Did COLL beat earnings last quarter?

In its 2026-05-07 report, COLL posted EPS of 1.76 USD versus a 1.52 USD estimate — a beat of 15.8%.

What is COLL's earnings track record?

Over the last 6 reported quarters with consensus data, COLL beat estimates 5 times (83%).

What is COLL's current P/E ratio and EPS?

COLL trades at a trailing P/E of 14.65 on trailing EPS of 2.335771418826637 USD.

What do analysts rate COLL?

Analyst consensus is "Buy" across 12 ratings (0 strong buy, 8 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 57.4 USD.